Safety was assessed via spontaneous reporting and review of subject diaries. RESULTS Clinical and statistically significant superiority to no treatment in terms of enhancing moisturization and desquamation per D-SQUAME® analysis at Day 2 and Day 14 (-2.51 and -3.07 from baseline, respectively; p less then 0.0001) was achieved. Treatment success as assessed by the investigator (via the Dry Skin Scale) and subject's self-assessment also indicated statistically significant improvements were achieved with the lactic acid/ceramide lotion (p less then 0.0001). No adverse events were reported during the study. https://www.selleckchem.com/products/apg-2449.html CONCLUSION The lactic acid/ceramide lotion provided a statistically significant and clinically meaningful improvement in moisturization and desquamation. CLINICALTRIALS.GOV IDENTIFIER NCT04085809.Pyoderma gangrenosum (PG) is a rare ulcerative skin disease commonly associated with pathergy and systemic comorbidities. We present the case of a patient who experienced two episodes of PG following consecutive dermatologic surgeries to the left hand. The initial PG ulcerations occurred simultaneously following Mohs surgery and a standard elliptical excision. Five months later, her PG recurred after Mohs surgery. Our patient denied a history of PG, however, further questioning elicited a medical history significant for Crohn's disease. Dermatologists and Mohs surgeons should consider the diagnosis when evaluating patients with poor postoperative wound healing. Unfortunately, a delay in diagnosis often occurs, as the presentation of postsurgical PG can mimic other common skin conditions. Awareness of PG prior to dermatologic surgery is critical to prevent further postoperative complications and unnecessary debridement.We present two cases of lymphangioma circumscriptum (LC) that demonstrated characteristics of half-and-half lacunae or hypopyon sign in dermoscopy. The first case was that of a 19-year-old female patient with localized lymphangioma since childhood, presenting with continuous oozing of blood and fluid from the lesion. The second patient presented with extensive disease with verrucous growths and clear vesicles over the right chest wall. Both patients reported an impact on their quality of life due to constant oozing of the lesions. The magnetic resonance imaging showed depth and extent in localized versus extensive forms of the same condition. A lipectomy was performed on both patients to destroy subcutaneous connecting lymphatics, which caused significant symptomatic improvement in oozing of blood and fluid, which had been present since childhood in both patients. However, we observed a recurrence in the second patient after six months.INTRODUCTION Anogenital warts (AGWs) are one of the leading sexually transmitted infections in the world. This condition poses a number of challenges to dermatologists, including the reluctance of patients to consult a physician and the high likelihood of relapse. Individuals with AGWs suffer a substantial psychological morbidity. Intralesional immunotherapy with the measles, mumps, and rubella (MMR) vaccine has been reported to be an effective treatment for warts. However, literature on the efficacy of intralesional immunotherapy with the MMR vaccine for the treatment of anogenital warts is sparse. OBJECTIVE We sought to determine the efficacy of the MMR vaccine for the treatment of anogenital warts at an outpatient dermatology department in Government Medical College Haldwani in India. METHODS This was a hospital-based, longitudinal study the included 35 patients. In patients with genital warts, 0.5mL of the MMR vaccine after reconstitution with distilled water was injected intradermally into their single largest wart. Injections were given every three weeks until a maximum of three injections was achieved. Pre- and posttreatment photographs were assessed to compare the degree of reduction in the size and number of warts. The therapeutic response was evaluated as follows No response ( less then 50% reduction in the number of warts), Relative response (50%-99% reduction), complete response (100% reduction). RESULTS On average, a 42.4-percent response was observed in the first three weeks after administering the MMR vaccine, which increased to 75.8 percent after the second vaccine at six weeks and nearly 98 percent after the last vaccine at nine weeks. CONCLUSION Our results suggest that intralesional immunotherapy with the MMR vaccine can serve as a safe and effective therapy for the treatment of AGWs.BACKGROUND Despite being an effective treatment for melasma, there have been limited reports on the long-term efficacy of intradermal tranexamic acid (TA) injection. OBJECTIVE This study sought to evaluate the 48-week efficacy of a 4mg/mL intradermal TA injection for the treatment of melasma. METHODS Five female patients with melasma participated in the 48-week follow-up after receiving 4-mg/mL intradermal TA injections on the face every two weeks for seven sessions and a sunscreen prescription. Assessments were performed at baseline and Weeks 4, 8, 12, 16, and 48 using the modified Melasma Area Severity Index (mMASI) score, melanin index, and patient satisfaction score. Safety and adverse effects were also evaluated. RESULTS The mean (standard deviation) age of patients was 53.6 (8.14) years and Fitzpatrick Skin Type IV (60%) and Fitzpatrick Skin Type V (40%) were observed. The mean (standard deviation) duration of melasma was 7.6 (2.51) years and 60 percent of participants reported a family history of melasma. There was a significant decrease in mMASI score and melanin index at 16 weeks, without a statistically significant improvement of mMASI score at 48 weeks. Melasma recurrence was observed in 60 percent of the participants, with higher mMASI scores recorded, but the severity remained less than at baseline. The patient satisfaction score was lower from Week 16 to Week 48. Interestingly, a statistically significant decrease in the melanin index was observed up to Week 48, with no serious adverse effects. CONCLUSION The 4-mg/mL intradermal TA injection yields significant efficacy at Week 16; however, melasma recurrence occurred during the 48-week follow-up. In addition to tranexamic acid injections, maintenance therapy and sun protection should be considered for patients with melasma.